Latest Market News

Forrestania Resources has updated the opening date of its Share Purchase Plan to 9 December 2025, aligning it with key corporate events and offering shareholders a chance to buy shares at $0.175 each alongside new option incentives.

Sea Forest Limited launches a $20.5 million IPO on the ASX to scale production and commercialisation of SeaFeed™, a scientifically validated livestock feed additive that cuts methane emissions by up to 80% while boosting productivity.

Venus Metals Corporation has acknowledged an on-market takeover bid from QGold at $0.17 per share, matching the last closing price. The Venus Board advises shareholders to take no immediate action as they assess the offer’s value against the company’s substantial asset base.

Euroz Hartleys Group Limited reported a robust FY2025 with an 87.7% jump in net profit and a strong start to FY2026, driven by increased brokerage and capital markets activity.

Sequoia Financial Group has acknowledged that ASIC’s civil penalty proceedings against its subsidiary InterPrac are material and confirmed timely disclosure to the market following formal notification.

Race Oncology Limited has secured shareholder approval for a replacement Constitution at its 2025 Annual General Meeting, updating its corporate governance framework to align with current regulatory standards.

Wesfarmers Limited announces a fully franked special dividend of AUD 0.40 per share alongside a $1.10 capital return, both payable on December 4, 2025. Eligible shareholders can participate in the Dividend Investment Plan for the dividend component, marking a significant move in the company’s 2025 capital management strategy.

Wesfarmers has set the allocation price for shares issued under its Dividend Investment Plan for the special dividend at $81.0055, with just over 12% of shareholders opting in. Shares will be allocated on 4 December 2025.

Elanor Investors Group has extended deadlines for a $125 million investment from Rockworth Capital Partners and the acquisition of Firmus, with a key shareholder meeting now scheduled for late January 2026.

Alfabs Australia Limited reported robust financial gains in FY2025, including a maiden dividend and major contract completion, while signaling cautious optimism for 2026 amid softer markets and uncertain project pipelines.

Chrysos Corporation reports nearly one million monthly PhotonAssay samples and reiterates strong FY26 revenue guidance, while unveiling next-gen assay technologies and global expansion plans.

Chrysos Corporation reported record FY25 financial results, driven by strong global demand for its innovative PhotonAssay™ technology. The company expanded its footprint, enhanced sustainability credentials, and strengthened governance, positioning itself for continued growth.